TOI Q2 revenue $119.8M (+21.5% YoY); net loss $17.0M; reaffirms FY guidance

Oncology Institute, Inc.

2025-Q2 EPS reported -$0.35 revenue$224,208,000

Consolidated revenue of $119.8M, up 21.5% YoY from $98.6M; gross profit $17.5M, up 34.4%.
Net loss $17.0M vs $15.5M; diluted EPS $(0.15) vs $(0.17); Adjusted EBITDA $(4.1)M vs $(8.7)M.
Pharmacy revenue $62.6M with >$11M gross profit; over 40% YoY growth.
Expanding capitated partnership with Elevance into two new Florida counties (more than double lives) and with Silver Summit in Nevada.
Reaffirms full-year 2025 guidance; expects revenue at high end of range and positive Adjusted EBITDA by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.